Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Japan Cytomegalovirus (CMV) Infection Market Insights, Epidemiology and Market Forecasts 2016-2023 - Research and Markets

Research and Markets
Posted on: 17 Oct 16

Research and Markets has announced the addition of the "Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast - 2023 -Japan" drug pipelines to their offering.

Japan Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast 2023 provides an overview of the disease and market size of the CMV for Japan.

It also includes historical and forecasted epidemiological data for the CMV Prevalent, Diagnosed and Treatable Cases, CMV Patients among Transplants, Infant Patients at High Risk of CMV and HIV Patients at High Risk of CMV from 2013-2023.

The total number of Diagnosed Cytomegalovirus (CMV) Infection cases is expected to increase at a CAGR of 0.056% to 7,355 cases in 2023. Out of all these high risk categories, Infants have comparatively higher number of CMV prevalent cases than HIV and Transplant patients in Japan. The market size for Cytomegalovirus (CMV) Infection shall reach to USD 68.1 Million by the end of 2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by our team of industry experts.

Key Topics Covered:

  1. Cytomegalovirus Infections
  2. Disease Overview
  3. Symptoms of cytomegalovirus (CMV) Infection
  4. Etiology
  5. Risk Factors
  6. Pathogenesis of human cytomegalovirus
  7. Pathophysiology of cytomegalovirus infection
  8. Diagnosis
  9. Treatment Algorithm for Cytomegalovirus Infections
  10. Treatment for Congenital CMV Infection
  11. Treatment of Ganciclovir resistant CMV
  12. Treatment Guidelines
  13. Recommendations for Treating Cytomegalovirus Infections
  14. Disease Management
  15. Epidemiology and Patient Population
  16. Assumptions and Rationale
  17. Total CMV Prevalent, Diagnosed and Treatable Cases
  18. CMV Patients among Transplants
  19. Infant Patients at High Risk of CMV
  20. HIV Patients at High Risk of CMV in Japan
  21. Unmet Medical Needs
  22. Marketed Products

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/nfgqqp/cytomegalovirus

View source version on businesswire.com: http://www.businesswire.com/news/home/20161017005537/en/

Business Wire
www.businesswire.com

Last updated on: 17/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.